Immunovant Inc

IMVT · NASDAQ · Healthcare / Biotechnology

34.18USD-0.87 (-2.48%)

Price History

Full chart

Market Stats

Previous Close35.05

Open34.71

Day Range33.87 – 34.84

52-Week Range21.86 – 45.42

Volume864.69K

Market Cap7.26B

P/E (TTM)0.00

Forward P/E0.00

EPS-2.56

Dividend Yield0.00%

Beta0.94

50-Day Avg33.11

200-Day Avg32.12

About

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Eric Venker M.D., Pharm.D.
Employees315
Headquarters1000 Park Forty Plaza, Durham, NC, United States, 27713, USA
Websitehttps://immunovant.com

Leadership

Dr. Frank M. Torti M.B.A., M.D.Executive Chairperson of the Board · b. 1979
Dr. Eric Venker M.D., Pharm.D.CEO & Director · b. 1987
Mr. Tiago M. Girao CPAChief Financial Officer · b. 1979
Ms. Melanie Gloria B.S.N.Chief Operating Officer · b. 1978
Dr. Jay S. Stout M.S., Ph.D.Chief Technology Officer · b. 1963
Mr. Christopher A. Van Tuyl Esq., J.D.Chief Legal Officer & Corporate Secretary · b. 1975
Ms. Christine BlodgettSenior Vice President of Human Resources
Ms. Becky MerlinaSenior VP & Global Head of Quality
Ms. Yan Zheng M.S., Ph.D.Senior Vice President of Biostatistics, Programming & Data Management
Ms. Sheetal Patel M.B.A., M.D., M.S.Senior Vice President of Clinical Development

Financials

Income Statement

Currency: USD	2018-03-31	2018-12-31	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31	2024-03-31	2025-03-31	2026-03-31
Total Revenue	-	-	-	0	0	0	0	0	0	0
Cost of Revenue	-	-	-	21.00K	998.00K	1.23M	1.32M	231.00K	377.00K	409.00K
Gross Profit	-	-	-	-21.00K	-998.00K	-1.23M	-1.32M	-231.00K	-377.00K	-409.00K
Operating Expense	-	-	-	59.66M	107.12M	154.80M	206.95M	269.98M	437.77M	532.49M
Operating Income	-136.74M	-450	-450	-59.68M	-108.12M	-156.03M	-208.28M	-270.21M	-438.15M	-532.90M
EBITDA	-	-	-28.41K	-65.64M	-108.05M	-156.69M	-198.28M	-258.54M	-412.57M	-504.98M
Net Income	-136.74M	-450	-450	-66.39M	-107.43M	-156.73M	-210.96M	-259.34M	-413.84M	-505.61M
R&D	135.26M	-	25.73M	47.93M	68.60M	101.81M	160.26M	212.93M	360.92M	456.66M
Interest Expense	0	0	0	625.00K	0	655.00K	12.48M	49.90M	-	-

Balance Sheet

Currency: USD	2018-03-31	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31	2024-03-31	2025-03-31	2026-03-31
Total Assets	113.17K	405.00K	109.39M	412.49M	515.56M	405.84M	666.71M	776.22M	957.57M
Total Liabilities	1.61M	380.45K	15.32M	21.01M	45.74M	43.34M	48.95M	68.78M	104.97M
Total Equity	-1.50M	24.55K	94.07M	391.48M	469.82M	362.49M	617.76M	707.45M	852.59M
Cash	-	325.00K	100.57M	400.15M	493.82M	376.53M	635.37M	713.97M	902.11M
Total Debt	-	300.00K	3.19M	3.42M	2.36M	1.22M	138.00K	98.00K	72.00K
Net Debt	-	-25.00K	-97.38M	-396.73M	-491.45M	-375.31M	-635.23M	-713.87M	-902.04M

Cash Flow

Currency: USD	2018-03-31	2018-12-31	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31	2024-03-31	2025-03-31	2026-03-31
Operating Cash Flow	-128.30M	-	-28.55M	-53.36M	-83.33M	-106.11M	-188.19M	-214.23M	-375.87M	-407.31M
Investing Cash Flow	-52.00K	-	-52.00K	-31.00K	-210.00K	-254.00K	-197.00K	-360.00K	-759.00K	-8.00K
Financing Cash Flow	128.30M	325.00K	35.58M	146.97M	383.11M	200.13M	70.89M	472.43M	454.49M	595.76M
Capital Expenditure	52.00K	0	52.00K	31.00K	210.00K	254.00K	197.00K	360.00K	759.00K	8.00K
Free Cash Flow	-128.30M	-	-28.60M	-53.39M	-83.54M	-106.37M	-188.39M	-214.59M	-376.63M	-407.32M
FCF to OCF	100.00%	-	100.18%	100.06%	100.25%	100.24%	100.10%	100.17%	100.20%	100.00%

Earnings

Report Date	Jun 12, 2019	Aug 12, 2019	Nov 6, 2019	Feb 14, 2020	Jun 29, 2020	Aug 12, 2020	Nov 12, 2020	Feb 16, 2021	Jun 1, 2021	Aug 9, 2021	Nov 5, 2021	Feb 4, 2022	Jun 8, 2022	Aug 5, 2022	Nov 4, 2022	Feb 3, 2023	May 22, 2023	Aug 10, 2023	Nov 9, 2023	Feb 12, 2024	May 29, 2024	Aug 6, 2024	Nov 7, 2024	Feb 6, 2025	May 29, 2025	Aug 11, 2025	Nov 10, 2025	Feb 6, 2026	May 20, 2026	Aug 6, 2026	Nov 9, 2026
EPS Estimate	0.00	0.00	0.00	-0.25	-0.28	-0.33	-0.30	-0.25	-0.34	-0.31	-0.27	-0.31	-0.38	-0.40	-0.36	-0.37	-0.41	-0.44	-0.46	-0.42	-0.43	-0.52	-0.59	-0.75	-0.71	-0.67	-0.73	-0.69	-0.63	-0.66	-0.73
EPS Actual	0.00	0.01	-0.25	-0.28	-0.38	-0.38	-0.25	-0.32	-0.29	-0.31	-0.35	-0.36	-0.41	-0.35	-0.41	-0.49	-0.46	-0.57	-0.45	-0.36	-0.52	-0.60	-0.74	-0.76	-0.64	-0.71	-0.65	-0.54	-0.67	-0.75	-0.47
Surprise	-	-	-	-12.00%	-35.71%	-15.15%	16.67%	-28.00%	14.71%	0.00%	-29.63%	-16.13%	-7.89%	12.50%	-13.89%	-32.43%	-12.20%	-29.55%	2.17%	14.29%	-20.93%	-15.38%	-25.42%	-1.33%	10.11%	-5.97%	10.96%	21.74%	-6.35%	-13.64%	35.62%
Timing	-	-	After-hours	Pre-market	Pre-market	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	After-hours	After-hours	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market

Key Statistics & Ratios

Market Cap7.26B

Enterprise Value5.40B

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book8.58

EPS-2.56

Book Value4.18

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-565.61M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-80.10%

Return on Assets-46.73%

Shares Outstanding206.55M

Shares Float91.77M

Beta0.94

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Buy

Based on 17 analystsTarget 48.88

Strong Buy
11
Buy
2
Hold
4

Ownership Breakdown

Institutions: 55.01%
Insiders: 56.01%
Retail / Other: 0.00%

Top Institutional Holders

FMR Inc
16.19M7.84%
Deep Track Capital, LP
9.34M4.52%
BlackRock Inc
7.18M3.48%
Farallon Capital Management, L.L.C.
5.80M2.81%
Baker Bros Advisors LP
5.44M2.63%
State Street Corp
4.62M2.24%
Morgan Stanley - Brokerage Accounts
4.53M2.20%
TCG Crossover Management, LLC
4.46M2.16%
Vanguard Portfolio Management, LLC
3.91M1.89%
Vanguard Capital Management, LLC
3.64M1.76%
Jennison Associates LLC
3.31M1.60%
RTW INVESTMENTS, LLC
3.18M1.54%
ADAR1 Capital Management LLC
2.33M1.13%
Geode Capital Management, LLC
2.23M1.08%
T. Rowe Price Investment Management,Inc.
2.22M1.08%

Top Fund Holders

Fidelity Growth Company Fund
5.09M2.47%
Vanguard MStar Total Stk Mkt Idx Invest
3.02M1.46%
State Street® SPDR® S&P® Biotech ETF
2.26M1.09%
iShares Russell 2000 ETF
2.19M1.06%
Vanguard Small Cap Index
2.09M1.01%